| Literature DB >> 35953816 |
Dong Wang1, Ning Fan1, Xin Wang2, Yandong Sun2, Ge Guan1, Jianhong Wang1,2, Xiaodan Zhu2, Yunjin Zang1,2, Jinzhen Cai3,4, Yuan Guo5,6.
Abstract
BACKGROUND: Liver transplantation is one of the most effective treatments for end-stage liver disease. Split liver transplantation (SLT) can effectively improve the utilization efficiency of grafts. However, split liver transplantation still faces shortcomings and is not widely used in surgery. How to improve the effective transplantation volume of split liver transplantation and promote the postoperative recovery of patients has important clinical significance.Entities:
Keywords: IV segment; Ischemia; P4 reconstruction; Split liver transplantation
Mesh:
Year: 2022 PMID: 35953816 PMCID: PMC9367133 DOI: 10.1186/s12893-022-01761-2
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Fig. 2The ischemic of extended right grafts in SLT before and after IV-segment portal vein reconstruction. A The ischemic region in the ERG and ‘a’ mean the ischemic area. B The IV segment was reconstructed and we can find that the ischemic region was decreased. ‘b’ stands for the ischemic region. C The reconstruction vein in the extended right graft, ‘d’ means the reconstruction vein. E The reconstruction vein was tested by ultrasound, we can see the blood vessel patency (d)
Fig. 1The IV segment portal vein reconstruction. A The extended right grafts. The ‘a stands for the left portal vein, and ‘b’ and ‘c’ mean the IV segment portal vein. B Iliac vein of dornor. C The reconstruction of IV-segment and left portal vein by the iliac vein. ‘d’ stand for the reconstruction vein. D The reconstruction vein by the color doppler ultrasound
Recipient characteristics
| No | Gender | Blood type | Age (year) | Height (cm) | Weight (kg) | BMI (kg/m2) | GRWR (%) | IV segment portal vein reconstruction |
|---|---|---|---|---|---|---|---|---|
| Patient 1 | Female | B | 38 | 177 | 63 | 20.1 | 1.85 | Yes |
| Patient 2 | Male | O | 15 | 170 | 43 | 14.9 | 2.92 | No |
| Patient 3 | Female | B | 42 | 160 | 60 | 23.4 | 2.40 | Yes |
| Patient 4 | Male | O | 52 | 168 | 70 | 24.8 | 1.99 | Yes |
| Patient 5 | Male | O | 43 | 180 | 84 | 25.9 | 1.24 | No |
| Patient 6 | Female | O | 42 | 163 | 64 | 24.1 | 2.29 | No |
| Patient 7 | Female | A | 59 | 150 | 40 | 17.8 | 2.83 | No |
| Patient 8 | Male | O | 39 | 160 | 62 | 24.2 | 1.25 | Yes |
| Patient 9 | Female | O | 59 | 150 | 56 | 24.9 | 1.91 | Yes |
| Patient 10 | Male | O | 32 | 172 | 77 | 26 | 1.76 | No |
| Patient 11 | Male | A | 69 | 170 | 77 | 26.6 | 1.68 | Yes |
| Patient 12 | Male | A | 25 | 165 | 59 | 21.7 | 1.88 | Yes |
| Patient 13 | Male | B | 52 | 170 | 70 | 24.2 | 1.74 | No |
| Patient 14 | Male | B | 45 | 178 | 63 | 19.9 | 2.21 | No |
| Patient 15 | Female | O | 69 | 160 | 52 | 20.3 | 1.97 | Yes |
| Patient 16 | Female | A | 63 | 158 | 55 | 22 | 1.86 | Yes |
| Patient 17 | Female | O | 15 | 173 | 58 | 19.4 | 2.62 | Yes |
| Patient 18 | Male | B | 63 | 171 | 74.5 | 24.5 | 1.49 | Yes |
| Patient 19 | Female | B | 49 | 165 | 61 | 22.4 | 2.10 | Yes |
| Patient 20 | Male | A | 37 | 170 | 65 | 21.5 | 1.89 | Yes |
| Patient 21 | Male | O | 51 | 178 | 78 | 24.6 | 1.34 | No |
BMI body mass index, GRWR Graft Volume/Recipient Body Weight Ratio
The characteristics in the group of IV segment portal vein reconstruction
| Characteristics | IV segment portal vein reconstruction | P-value | |
|---|---|---|---|
| Yes (n = 13) | No (n = 8) | ||
| Age, years | 47.69 ± 16.89 | 42.38 ± 13.67 | 0.46 |
| BMI, kg/m2 | 22.75 ± 2.18 | 22.18 ± 4.13 | 0.68 |
| Platelet, 109/L | 142.08 ± 116.66 | 107.75 ± 53.00 | 0.45 |
| GRWR, % | 1.915 ± 0.35 | 2.04 ± 0.63 | 0.57 |
| Hospitalization time, days | 46.31 ± 11.15 | 40.5 ± 14.33 | 0.31 |
| ALT, U/L | 49.69 ± 24.49 | 19 ± 7.75 | 0.003 |
| AST, U/L | 68.62 ± 32.19 | 32.38 ± 29.14 | 0.018 |
| Bil, μmol/L | 145.90 ± 261.40 | 36.16 ± 40.76 | 0.26 |
| Serum albumin, g/L | 32.72 ± 5.90 | 35.75 ± 7.85 | 0.33 |
| PT, s | 16.04 ± 4.33 | 16.19 ± 3.75 | 0.94 |
| GGT, U/L | 101.15 ± 93.65 | 55.38 ± 71.42 | 0.25 |
| Creatinine, μmol/L | 138.09 ± 245.01 | 70.49 ± 29.12 | 0.48 |
| Gender | |||
| Female | 7 | 2 | 0.37 |
| Male | 6 | 6 | |
| Blood type | |||
| A | 4 | 1 | 0.51 |
| B | 4 | 2 | |
| O | 5 | 5 | |
| Cause of disease | |||
| Liver failure | 7 | 4 | 1 |
| Tumor | 6 | 4 | |
BMI body mass index, GRWR Graft Volume/Recipient Body Weight Ratio, GGT γ –glutamyltransferase, TBil total bilirubin; PT Prothrombin time, ALT glutamic-pyruvic transaminase, AST glutamic oxalacetic transaminase
The operation characteristics in the two groups
| Characteristics | IV segment portal vein reconstruction | P-value | |
|---|---|---|---|
| Yes (n = 13) | No (n = 8) | ||
| The weight of the graft | 1236.38 ± 159.37 | 1187 ± 200.37 | 0.56 |
| Total OR time, min | 555.63 ± 90.57 | 590.231 ± 113.24 | 0.47 |
| Anhepatic phase, min | 50.63 ± 8.28 | 61 ± 20.00 | 0.18 |
| Hemorrhage, mL | 1437.5 ± 821.04 | 1361.54 ± 818.07 | 0.84 |
| Red blood cells transfusion volume, u | 10.06 ± 6.56 | 10.5 ± 5.26 | 0.87 |
| Plasma transfusion volume, mL | 987.75 ± 534.99 | 1164.62 ± 651.86 | 0.53 |
| ICU hospitalization time, day | 6.75 ± 8.24 | 6.85 ± 4.04 | 0.97 |
| Hospitalization time of OR, day | 33.5 ± 12.35 | 36.54 ± 8.93 | 0.52 |
The liver function after SLT in two groups
| Characteristics | IV segment portal vein reconstruction | P-value | ||
|---|---|---|---|---|
| No (n = 8) | Yes (n = 13) | |||
| POD-1 | ALT, U/L | 904.13 ± 635.23 | 443.77 ± 232.17 | 0.03 |
| AST, U/L | 740 ± 760.79 | 676.77 ± 234.22 | 0.19 | |
| Serum albumin, g/L | 44.98 ± 8.48 | 39.92 ± 5.49 | 0.11 | |
| PT, s | 19.05 ± 2.27 | 20.61 ± 6.51 | 0.53 | |
| Platelet, 109/L | 70.75 ± 27.78 | 81.38 ± 57.63 | 0.63 | |
| POD-3 | ALT, U/L | 491 ± 427.65 | 276.69 ± 177.28 | 0.12 |
| AST, U/L | 110.25 ± 59.56 | 183.38 ± 169.79 | 0.26 | |
| Serum albumin, g/L | 43.09 ± 6.49 | 39.42 ± 4.75 | 0.15 | |
| PT, s | 17.08 ± 2.59 | 16.75 ± 3.32 | 0.82 | |
| Platelet, 109/L | 65.13 ± 31.84 | 74.69 ± 68.35 | 0.72 | |
| POD-5 | ALT, U/L | 164.75 ± 149.57 | 143.54 ± 87.61 | 0.69 |
| AST, U/L | 29.5 ± 7.56 | 50 ± 34.27 | 0.12 | |
| Serum albumin, g/L | 40.09 ± 6.35 | 41.17 ± 4.21 | 0.64 | |
| PT, s | 16.33 ± 2.42 | 15.05 ± 2.44 | 0.26 | |
| Platelet, 109/L | 86.5 ± 57.5227 | 64.692 ± 45.3604 | 0.35 | |
| POD-6 | ALT, U/L | 109.5 ± 65.42 | 114.62 ± 66.85 | 0.87 |
| AST, U/L | 31.63 ± 23.69 | 37.77 ± 28.54 | 0.62 | |
| Serum albumin, g/L | 38.9 ± 3.49 | 42.22 ± 3.22 | 0.04 | |
| PT, s | 15.53 ± 2.03 | 14.4 ± 2.27 | 0.27 | |
| Platelet, 109/L | 96.37 ± 65.73 | 71 ± 46.88 | 0.34 | |
| POD-7 | ALT, U/L | 72.25 ± 50.40 | 95.31 ± 61.20 | 0.38 |
| AST, U/L | 27.75 ± 14.59 | 46 ± 39.22 | 0.23 | |
| Serum albumin, g/L | 37.59 ± 3.97 | 40.33 ± 4.05 | 0.15 | |
| PT, s | 15.08 ± 1.85 | 14.95 ± 3.36 | 0.92 | |
| Platelet, 109/L | 94.5 ± 61.63 | 83.23 ± 59.11 | 0.68 | |
PT Prothrombin time, ALT glutamic-pyruvic transaminase, AST glutamic oxalacetic transaminase